Literature DB >> 3689633

Lack of correlation between methotrexate concentrations in serum, saliva and sweat after 24 h methotrexate infusions.

H Schrøder1, K B Jensen, M Brandsborg.   

Abstract

1 Methotrexate (MTX) concentrations were studied in serum, mixed saliva and sweat during and after 24 h continuous MTX infusions (0.5-6 g m-2) in 14 patients with various malignant diseases. 2 The serum-MTX concentrations declined in a biphasic manner, but the MTX elimination in saliva and sweat varied to a much greater extent. 3 Saliva/serum and sweat/serum ratios during the MTX infusion were 2.3% and 0.55% respectively. The ratios had increased significantly 20 and 44 h postinfusion. 4 No correlations were demonstrated between salivary- and serum-MTX concentrations during the MTX infusion or 20 and 44 h later. 5 Markedly delayed renal MTX excretions were demonstrated in two patients. In one of them the salivary MTX elimination was also retarded, whereas this was not seen in the other one. 6 We conclude that measurements of MTX concentrations in mixed saliva cannot substitute for serum-MTX determinations in the monitoring of patients after 24 h MTX infusions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3689633      PMCID: PMC1386317          DOI: 10.1111/j.1365-2125.1987.tb03208.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease.

Authors:  P A DI SANT'AGNESE; R C DARLING; G A PERERA; E SHEA
Journal:  Pediatrics       Date:  1953-11       Impact factor: 7.124

2.  A rapid, radiochemical-ligand binding assay for methotrexate.

Authors:  B A Kamen; P L Takach; R Vatev; J D Caston
Journal:  Anal Biochem       Date:  1976-01       Impact factor: 3.365

3.  Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

Authors:  W E Evans; C B Pratt; R H Taylor; L F Barker; W R Crom
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Enzymatic assay for methotrexate with a centrifugal analyzer (Cobas-Bio)

Authors:  A M Imbert; T Pignon; N Lena
Journal:  Clin Chem       Date:  1983-06       Impact factor: 8.327

5.  Methotrexate in the plasma and cerebrospinal fluid of children treated with intermediate dose methotrexate.

Authors:  C Rechnitzer; E Scheibel; J Hendel
Journal:  Acta Paediatr Scand       Date:  1981-09

6.  Salivary elimination of cyclophosphamide in man.

Authors:  W A Ritschel; G Bykadi; E J Norman; R J Cluxton; D Denton
Journal:  J Clin Pharmacol       Date:  1981 Nov-Dec       Impact factor: 3.126

7.  Methotrexate serum and saliva concentrations in patients.

Authors:  A J Patterson; W A Ritschel; D Zellner; S H Kim
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1981-09

8.  Protein binding of methotrexate in sera from normal human beings: effect of drug concentration, pH, temperature, and storage.

Authors:  J W Paxton
Journal:  J Pharmacol Methods       Date:  1981-05

9.  The protein binding of methotrexate in the serum of patients with neoplastic disease.

Authors:  W H Steele; J R Lawrence; J F Stuart; C A McNeill
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

10.  The kinetics of salivary elimination of cyclophosphamide in man.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1979-11       Impact factor: 4.335

View more
  4 in total

Review 1.  Therapeutic drug monitoring in saliva. An update.

Authors:  R K Drobitch; C K Svensson
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

Review 2.  Saliva as a Future Field in Psoriasis Research.

Authors:  Farah Asa'ad; Marco Fiore; Aniello Alfieri; Paolo Daniele Maria Pigatto; Chiara Franchi; Emilio Berti; Carlo Maiorana; Giovanni Damiani
Journal:  Biomed Res Int       Date:  2018-05-20       Impact factor: 3.411

3.  Critical factors for the reversal of methotrexate cytotoxicity by folinic acid.

Authors:  S Bernard; M C Etienne; J L Fischel; P Formento; G Milano
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

4.  Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics.

Authors:  Teruo Murakami; Nobuhiro Mori
Journal:  Pharmaceuticals (Basel)       Date:  2012-08-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.